## Gabrielle McCallum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2495275/publications.pdf

Version: 2024-02-01

361413 377865 1,337 55 20 34 citations h-index g-index papers 57 57 57 1328 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Bronchiectasis - Exercise as Therapy (BREATH): rationale and study protocol for a multi-center randomized controlled trial. Trials, 2022, 23, 292.	1.6	2
2	Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial. Pediatric Infectious Disease Journal, 2022, 41, 549-555.	2.0	10
3	Reducing exacerbations in children and adults with primary ciliary dyskinesia using erdosteine and/or azithromycin therapy (REPEAT trial): study protocol for a multicentre, double-blind, double-dummy, 2×2 partial factorial, randomised controlled trial. BMJ Open Respiratory Research, 2022, 9, e001236.	3.0	O
4	Can Acute Cough Characteristics From Sound Recordings Differentiate Common Respiratory Illnesses in Children?. Chest, 2021, 159, 259-269.	0.8	4
5	Determinants of cough and caregivers' quality of life in pediatric asthma exacerbations. Pediatric Pulmonology, 2021, 56, 371-377.	2.0	2
6	European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. European Respiratory Journal, 2021, 58, 2002990.	6.7	95
7	Comparison of Profiles of First Nations and Non-First Nations Children With Bronchiectasis Over Two 5-Year Periods in the Northern Territory, Australia. Chest, 2021, 160, 1200-1210.	0.8	9
8	Clinical and research priorities for children and young people with bronchiectasis: an international roadmap. ERJ Open Research, 2021, 7, 00122-2021.	2.6	28
9	How does the Canadian Acute Respiratory Illness and Flu Scale relate to other scales in pediatric asthma exacerbations?. Journal of Asthma, 2021, , 1-7.	1.7	1
10	Factors associated with "Frequent Exacerbator―phenotype in children with bronchiectasis: The first report on children from the Australian Bronchiectasis Registry. Respiratory Medicine, 2021, 188, 106627.	2.9	7
11	Utility of a personalised <i>B</i> ronchiectasis <i>A</i> ction <i>M</i> anagement <i>P</i> li>lan (BAMP) for children with bronchiectasis: protocol for a multicentre, double-blind parallel, superiority randomised controlled trial. BMJ Open, 2021, 11, e049007.	1.9	2
12	Electronic cigarettes: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2020, 25, 1082-1089.	2.3	23
13	Latent class analysis to identify clinical profiles among indigenous infants with bronchiolitis. Pediatric Pulmonology, 2020, 55, 3096-3103.	2.0	6
14	A decade on: Followâ€up findings of indigenous children with bronchiectasis. Pediatric Pulmonology, 2020, 55, 975-985.	2.0	15
15	Efficacy of oral amoxicillin–clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial. Lancet Respiratory Medicine,the, 2019, 7, 791-801.	10.7	37
16	HOspitalised Pneumonia Extended (HOPE) Study to reduce the long-term effects of childhood pneumonia: protocol for a multicentre, double-blind, parallel, superiority randomised controlled trial. BMJ Open, 2019, 9, e026411.	1.9	2
17	Perspective: Using Bronchiectasis Action Management Plans for Children With Bronchiectasisâ€"Can It Improve Clinical Care?. Frontiers in Pediatrics, 2019, 7, 428.	1.9	3
18	Epidemiology of ocular trauma in the Indigenous vs nonâ€Indigenous population in the Top End. Clinical and Experimental Ophthalmology, 2019, 47, 995-999.	2.6	3

#	Article	IF	Citations
19	The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a $\hat{a}\in \hat{b}$ population., 2019,,.		O
20	The point prevalence of respiratory syncytial virus in hospital and community-based studies in children from Northern Australia: studies in a â€⁻high-risk' population. Rural and Remote Health, 2019, 19, 5267.	0.5	0
21	Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine. Vaccine, 2018, 36, 1736-1742.	3.8	13
22	â€~Good enough' is â€~not enough' when managing indigenous adults with bronchiectasis in Australia an New Zealand. Respirology, 2018, 23, 725-726.	d <sub>2.3</sub>	18
23	Defining lower airway bacterial infection in children with chronic endobronchial disorders. Pediatric Pulmonology, 2018, 53, 224-232.	2.0	26
24	Clinical course of chronic suppurative lung disease and bronchiectasis in Alaska Native children. Pediatric Pulmonology, 2018, 53, 1662-1669.	2.0	12
25	Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet, The, 2018, 392, 1197-1206.	13.7	51
26	Bacteria and viruses in the nasopharynx immediately prior to onset of acute lower respiratory infections in Indigenous Australian children. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1785-1794.	2.9	9
27	Propensity of pneumococcal carriage serotypes to infect the lower airways of children with chronic endobronchial infections. Vaccine, 2017, 35, 747-756.	3.8	12
28	Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. The Cochrane Library, 2017, 2017, CD009834.	2.8	18
29	Culture-specific programs for children and adults from minority groups who have asthma. The Cochrane Library, 2017, 2017, CD006580.	2.8	60
30	The Epidemiology of Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents. Frontiers in Pediatrics, 2017, 5, 27.	1.9	71
31	Feasibility of a Peer-Led Asthma and Smoking Prevention Project in Australian Schools with High Indigenous Youth. Frontiers in Pediatrics, 2017, 5, 33.	1.9	10
32	Risk factors for adverse outcomes of Indigenous infants hospitalized with bronchiolitis. Pediatric Pulmonology, 2016, 51, 613-623.	2.0	26
33	Toward Making Inroads in Reducing the Disparity of Lung Health in Australian Indigenous and New Zealand MÃ,,Âori Children. Frontiers in Pediatrics, 2015, 3, 9.	1.9	33
34	Three-Weekly Doses of Azithromycin for Indigenous Infants Hospitalized with Bronchiolitis: A Multicentre, Randomized, Placebo-Controlled Trial. Frontiers in Pediatrics, 2015, 3, 32.	1.9	28
35	Further clinical trials on macrolides for bronchiolitis in infants are unnecessary. Journal of Allergy and Clinical Immunology, 2015, 136, 1134-1135.	2.9	1
36	Culturally appropriate flipcharts improve the knowledge of common respiratory conditions among Northern Territory Indigenous families. Health Promotion Journal of Australia, 2015, 26, 150-153.	1.2	16

#	Article	IF	CITATIONS
37	Indigenous children from three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Pediatric Pulmonology, 2014, 49, 189-200.	2.0	85
38	Can mobile phone multimedia messages and text messages improve clinic attendance for <scp>A</scp> boriginal children with chronic otitis media? A randomised controlled trial. Journal of Paediatrics and Child Health, 2014, 50, 362-367.	0.8	28
39	Clinical pathways for chronic cough in children. The Cochrane Library, 2014, 2014, CD006595.	2.8	14
40	Retrospective review of 200 children hospitalised with acute asthma. Identification of intervention points: A single centre study. Journal of Paediatrics and Child Health, 2014, 50, 286-290.	0.8	5
41	Mobile phones support adherence and retention of indigenous participants in a randomised controlled trial: strategies and lessons learnt. BMC Public Health, 2014, 14, 622.	2.9	17
42	Respiratory Exacerbations in Indigenous Children From Two Countries With Non-Cystic Fibrosis Chronic Suppurative Lung Disease/Bronchiectasis. Chest, 2014, 146, 762-774.	0.8	39
43	Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. Trials, 2013, 14, 53.	1.6	16
44	Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2013, 1, 610-620.	10.7	157
45	Severity scoring systems: Are they internally valid, reliable and predictive of oxygen use in children with acute bronchiolitis?. Pediatric Pulmonology, 2013, 48, 797-803.	2.0	67
46	Accuracy of cough reporting by carers of Indigenous children. Journal of Paediatrics and Child Health, 2013, 49, E199-203.	0.8	19
47	Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis. PLoS ONE, 2013, 8, e70478.	2.5	32
48	A Single Dose of Azithromycin Does Not Improve Clinical Outcomes of Children Hospitalised with Bronchiolitis: A Randomised, Placebo-Controlled Trial. PLoS ONE, 2013, 8, e74316.	2.5	38
49	Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. , 2012, 12, CD009834.		11
50	Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. Trials, 2012, 13, 156.	1.6	14
51	Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial. BMC Pediatrics, 2012, 12, 122.	1.7	22
52	Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. Trials, 2011, 12, 94.	1.6	16
53	Singleâ€dose azithromycin versus seven days of amoxycillin in the treatment of acute otitis media in Aboriginal children (AATAAC): a double blind, randomised controlled trial. Medical Journal of Australia, 2010, 192, 24-29.	1.7	29
54	Age-Specific Cluster of Cases of Serotype 1 Streptococcus pneumoniae Carriage in Remote Indigenous Communities in Australia. Vaccine Journal, 2009, 16, 218-221.	3.1	18

#	Article	IF	CITATIONS
55	Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infectious Diseases, 2009, 9, 121.	2.9	51